Success Metrics

Completion Rate
0%(0/2)
Active Trials
1(11%)
Terminated
2(22%)

Phase Distribution

Ph phase_2
3
33%
Ph phase_1
4
44%
Ph phase_3
2
22%

Phase Distribution

4

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Terminated(2)
Other(6)

Detailed Status

unknown6
Terminated2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (44.4%)
Phase 23 (33.3%)
Phase 32 (22.2%)

Trials by Status

recruiting111%
terminated222%
unknown667%

Recent Activity

Clinical Trials (9)

Drug Details

Intervention Type
DRUG
Total Trials
9